Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 17,016 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Elevate Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age

NCT05084508
View directory record Official record
Conditions
Chickenpox
Interventions
Investigational varicella vaccine low potency, Investigational varicella vaccine medium potency, Investigational varicella vaccine high potency, Licensed varicella vaccine Lot 1, Licensed varicella vaccine Lot 2, Measles, mumps, and rubella vaccine, Hepatitis A vaccine, 13-valent pneumococcal conjugate vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
41
States / cities
Bryant, Arkansas • Jonesboro, Arkansas • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 30, 2026, 1:06 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma

NCT00636168
View directory record Official record
Conditions
High Risk Stage III Melanoma
Interventions
ipilimumab, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
20
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 30, 2026, 1:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

theFRESHstudy: FRequency of Eating and Its Influence on Satiety and Health

NCT02392897
View directory record Official record
Conditions
Healthy
Interventions
High Eating Frequency, Low Eating Frequency
Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Oct 30, 2026, 1:06 PM EDT
Withdrawn Phase 1Phase 2 Interventional

C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer

NCT02344810
View directory record Official record
Conditions
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Gastrointestinal Cancer, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Stage IIIA Esophageal Cancer, Stage IIIA Gastric Cancer, Stage IIIB Esophageal Cancer, Stage IIIB Gastric Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Gastric Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer
Interventions
c-Met inhibitor AMG 337, placebo, oxaliplatin, leucovorin calcium, fluorouracil, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 30, 2026, 1:06 PM EDT
Withdrawn Phase 2 Interventional

Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants

NCT04495010
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab, Ipilimumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
23
States / cities
Gilbert, Arizona • Tucson, Arizona • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2021 · Synced Oct 30, 2026, 1:06 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving Chemotherapy

NCT02097823
View directory record Official record
Conditions
Chemotherapy Induced Nausea and Vomiting
Interventions
Olanzapine, Aprepitant
Drug
Lead sponsor
Indiana University
Other
Eligibility
4 Years to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Oct 30, 2026, 1:06 PM EDT
Completed Phase 2 Interventional

Brentuximab for Newly Diagnosed Hodgkin Disease

NCT02398240
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
Brentuximab Vedotin, Doxorubicin, Vincristine, Rituximab
Drug
Lead sponsor
Mitchell Cairo
Other
Eligibility
1 Year to 29 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 30, 2026, 1:06 PM EDT
Completed Phase 2 Interventional

Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917

NCT00290940
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
CS-917, metformin hydrochloride, pioglitazone
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 70 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
66
States / cities
Birmingham, Alabama • Northport, Alabama • Mesa, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2007 · Synced Oct 30, 2026, 1:06 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Precise Oncology Interventions in Nutrition and Training (OnPoint)

NCT06534918
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Colorectal Cancer, Lymphoma
Interventions
Fitbit, Nutrition Course: Group Sessions, Physical Activity Program: Group Sessions, Nutrition Course: One on One Sessions with Registered Dietitian, Physical Activity Program: One on One Sessions with an Exercise Physiologist, Nutrition and Physical Activity Prescription
Other · Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 30, 2026, 1:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

To Reach Unrestricted Services for Transgender Women

NCT03877497
View directory record Official record
Conditions
Transgender Women, Substance Abuse, Hiv
Interventions
Adapted SBIRT-T for transgender women
Behavioral
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years and older · Male only
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 30, 2026, 1:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Canola Oil Multi-center Intervention Trial II

NCT03054779
View directory record Official record
Conditions
Cardiovascular Disease, Metabolic Syndrome
Interventions
Canola Oil, High oleic acid canola oil, Western diet oil combination
Other
Lead sponsor
Penn State University
Other
Eligibility
20 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 30, 2026, 1:06 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)

NCT01467479
View directory record Official record
Conditions
Hepatitis C
Interventions
Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a, Highly Active Antiretroviral Therapy (HAART)
Drug · Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
46
States / cities
Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 42 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 30, 2026, 1:06 PM EDT
Completed Not applicable Interventional

Physical Activities by Technology Help (PATH)

NCT03212079
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer, Oral Cancer
Interventions
Mycoach Smart Text, MyCoach on Amazon Alexa
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 30, 2026, 1:06 PM EDT
Active, not recruiting Not applicable Interventional Results available

Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer

NCT01342367
View directory record Official record
Conditions
Prostate Cancer
Interventions
Bicalutamide, Dutasteride, Finasteride, Radiation
Drug · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 30, 2026, 1:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of High Fat Meal on Cabotegravir

NCT02799264
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Cabotegravir 30 mg
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 30, 2026, 1:06 PM EDT
Active, not recruiting No phase listed Observational

DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive Biomarkers

NCT04165564
View directory record Official record
Conditions
Pulmonary Disease
Interventions
Institutional standard of care, Biosamples of airway and blood
Other
Lead sponsor
Boston University
Other
Eligibility
46 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 30, 2026, 1:06 PM EDT
Completed Early Phase 1 Interventional

Prospective Study of Personalized Approach to Inpatient Patients With Hyperglycemia

NCT03904199
View directory record Official record
Conditions
Hyperglycemia
Interventions
Insulin
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Oct 30, 2026, 1:06 PM EDT
Completed Not applicable Interventional Results available

Impact of Hearing Aid Service-delivery Model and Technology on Patient Outcomes

NCT03579563
View directory record Official record
Conditions
Presbycusis
Interventions
AUD fitting, OTC fitting, High-end HA, Low-end HA
Other · Device
Lead sponsor
Yu-Hsiang Wu
Other
Eligibility
55 Years to 85 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Iowa City, Iowa • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 10, 2024 · Synced Oct 30, 2026, 1:06 PM EDT
Active, not recruiting Not applicable Interventional

EXHIT ENTRE Implementation Trial of High Intensity Versus Low Intensity Strategy

NCT04921787
View directory record Official record
Conditions
Substance Use Disorders, Opioid Use Disorder, Severe, Opioid Use Disorder, Moderate
Interventions
Low Intensity, High Intensity
Other
Lead sponsor
Gavin Bart
Other
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Boston, Massachusetts • Minneapolis, Minnesota • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 30, 2026, 1:06 PM EDT
Suspended Phase 2Phase 3 Interventional

Ankle Manual Therapy for Ankle Sprains

NCT00888498
View directory record Official record
Conditions
Sprains and Strains
Interventions
Passive Positioning, High-Velocity, Low-Amplitude Stretch, Slow, Mobilization Stretch
Other
Lead sponsor
University of the Pacific
Other
Eligibility
16 Years to 60 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Stockton, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2015 · Synced Oct 30, 2026, 1:06 PM EDT
Terminated Phase 1Phase 2 Interventional

Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma

NCT06516887
View directory record Official record
Conditions
Advanced Lung Adenocarcinoma
Interventions
bemcentinib, pacritinib
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 30, 2026, 1:06 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003)

NCT05507450
View directory record Official record
Conditions
Dengue Disease, Dengue Virus
Interventions
V181 High-Potency Level, V181 Mid-Potency Level, V181 Low-Potency Level, Placebo
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
1,271 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
6
States / cities
San Diego, California • Miami, Florida • Rochester, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 30, 2026, 1:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Omega-3 Fatty Acids on Markers of Inflammation

NCT01129050
View directory record Official record
Conditions
Obesity, Hypertriglyceridemia, Insulin Resistance, Hypertension
Interventions
Fish Oil, Flaxseed Oil, Placebo
Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 30, 2026, 1:06 PM EDT
Completed Phase 1 Interventional

Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma

NCT02332850
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Isatuximab, Carfilzomib, Dexamethasone
Biological · Drug
Lead sponsor
Thomas Martin, MD
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
5
States / cities
San Francisco, California • Denver, Colorado • Hackensack, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 30, 2026, 1:06 PM EDT